文献速递浆细胞疾病

单克隆丙种球蛋白病的衰老特征分析揭示旁分泌衰老是抵御疾病进展的关键防御机制

Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression.
PubMed 文献 · Leukemia · 2025-03-31

该研究分析单克隆丙种球蛋白病患者来源的浆细胞,发现MGUS患者中衰老浆细胞显著多于SMM或MM患者。稳定MGUS和SMM患者骨髓微环境中存在局部旁分泌衰老激活及疾病特异性SASP特征,且与浆细胞负荷和克隆抗体显著相关;进展期患者则缺乏上述反应,提示旁分泌衰老激活失败是疾病进展的关键。

要点

  • MGUS患者衰老浆细胞显著多于SMM或MM患者。
  • 稳定MGUS和SMM患者骨髓微环境存在局部旁分泌衰老激活。
  • 进展期患者缺乏局部旁分泌衰老反应及疾病特异性SASP特征。

核心结论

  • 肿瘤特异性旁分泌衰老反应激活失败是单克隆丙种球蛋白病疾病进展的关键。

研究设计与样本

  • 研究鉴定单克隆丙种球蛋白病患者来源的浆细胞并分析其衰老特征,对稳定MGUS和SMM患者活检组织进行衰老浆细胞空间分析。

主要发现

  • MGUS患者衰老浆细胞显著多于SMM或MM患者。
  • 稳定MGUS和SMM患者活检显示骨髓微环境中局部旁分泌衰老激活。
  • 稳定MGUS和SMM患者具有疾病特异性SASP特征,与浆细胞负荷和克隆抗体显著相关。
  • 进展性MGUS、SMM及新诊断MM患者缺乏局部旁分泌衰老反应和疾病特异性SASP特征的强激活。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a plasma cell (PC) malignancy that is preceded by monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering multiple myeloma (SMM). MGUS and SMM PCs exhibit the same primary oncogenic abnormalities as MM but lack the end-organ damage that defines proliferative disease, suggesting that clonal PCs in these precursor conditions could exhibit senescence or senescence-like growth arrest. Herein we identified monoclonal gammopathy patient-derived PCs that exhibit senescence features and found that senescent PCs were significantly increased in MGUS patients compared to SMM or MM. Spatial analysis of senescent PCs in stable MGUS and SMM patient biopsies demonstrated the activation of local paracrine senescence in the bone marrow microenvironment. Stable MGUS and SMM patients also exhibited disease-specific senescence-associated secretory phenotype (SASP) signatures that significantly correlated with PC burden and clonal antibody. In contrast, progressing MGUS, SMM, and new MM patients lacked local paracrine senescence responses and robust activation of disease specific SASP signatures. Overall, these data suggest that failure to activate tumor-specific paracrine senescence responses is key to disease progression in monoclonal gammopathies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Borges GA, Diaz-delCastillo M, Guilatco AJ, et al. Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Leukemia. 2025. PMID: 40164720. doi:10.1038/s41375-025-02572-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。